Forbes January 3, 2025
Buried in the news from last month was an interesting nugget posted by Fierce Pharma: “Following a dinner at Trump’s Mar-a-Lago estate last week, Eli Lilly CEO David Ricks pointed to raising drug prices in other developed nations as a key strategy to reduce costs in the U.S., a potential focus of President-Elect Donald Trump’s administration.”
It seems to hint that international price referencing for certain prescription drugs may be on the table during the second Trump administration. Broadly, this is a system of price controls in which an average or minimum price across a group of countries with similar gross domestic output per capita can serve as an anchor towards which differing prices may converge over time.
During the...
Today's Sponsors
Today's Sponsor